The European & Developing Countries Clinical Trials Partnership (EDCTP) grants EUR 10 million over five years to “WANECAM 2” a unique collaboration between antimalarial drug researchers in Africa and Europe from ten academic institutions, a pharmaceutical company, Novartis, and a not-for-profit product development partnership (PDP), Medicines for Malaria Venture. Read the full article HERE.
Europe-Africa partnership spearheads development of next-generation antimalarial drug
May 3, 2019